Abstract
The use of sex hormones for the treatment of breast cancer probably contributed more to the management of the advanced disease than the advent of any other therapy. Their value in patients too ill for more severe treatment, their relative lack of debilitating side effects, and the long periods of remission that may be obtained, combine to give hormones a measure of advantage over any other therapy. But it is this very simplicity of use which has resulted in a relative lack of endeavour by clinical research workers to investigate their mode of action. There is little encouragement to investigate the features which might predict those patients who may benefit from hormone therapy when it is so easy to try the drugs clinically on all cases. Androgens or oestrogens can be administered without the patient being admitted to hospital, and the response of the tumour soon provides the answer as to whether or not the treatment will work.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Braunsberg, H., Irvine, W. T., James, V. H. T.: A comparison of steroid hormone concentrations in human tissues including breast cancer. Brit. J. Cancer 21, 714 (1967).
James, V. H. T.: Observations on the binding of testosterone to malignant mammary tumours and other tissues in vitro. Brit. J. Cancer 21, 703 (1967).
Bulbrook, R. D., Greenwood, F. C., Hayward, J. L.: Selection of breast cancer patients for adrenalectomy or hypophysectomy by determination of urinary 17-hydroxy corticosteroids and aetiocholanolone. Lancet 1960 I, 1154.
Hayward, J. L.: The possibility of predicting the response of patients with early breast cancer to subsequent endocrine ablation. Cancer Res. 25, 1135 (1965).
Spicer, C. C., Thomas, B. S.: Abnormal excretion of urinary steroids by women with early breast cancer. Lancet 1962 a I I, 1238.
Spicer, C. C., Thomas, B. S.: A comparison between the urinary steroid excretion of normal women and women with advanced breast cancer. Lancet 1962 b I I, 1235.
Thomas, B. S.: The relation between the urinary 17-hydroxy corticosteroids and 11-deoxy-17-oxosteroids and the fate of patients after mastectomy. Lancet 1964 I, 945.
Cantino, I. J., Gordan, G. S.: High dosage d 1 testolactone therapy of disseminated car-cinoma of the breast. Cancer 20, 458 (1967).
Chakmakjian, Z. H., Bethune, J. E.: Sodium sulfate treatment of hypercalcemia. New Engl. J. Med. 275, 862 (1966).
Co-operative Breast Cancer Group: Results of studies of the Co-operative Breast Cancer Group 1961–1963. Cancer Chemother. Rep. 41, Suppl. 1 (1964 a).
Co-operative Breast Cancer Group: Testosterone Propionate Therapy in Breast Cancer. J. Amer. med. Ass. 188, 1069 (1964 b).
Council on Drugs, Subcommittee on Breast and Genital Cancer, Committee on Research, American Medical Association: Androgens and Oestrogens in the treatment of disseminated mammary carcinoma; retrospective study of 944 patients. J. Amer. med. Ass. 172, 1271 (1960).
Council on Pharmacy and Chemistry. Current status of hormone therapy of advanced mammary cancer. J. Amer. med. Ass. 146, 471 (1951).
Crowley, L. G., Demetriou, J., Macdonald, I., Kotin, P., Kushinsky, S., Donovan, A. J.
Levels of exogenous oestrogens in tissues in human mammary carcinoma. Surg. Forum 13, 103 (1962).
Cutler, M., Schlemenson, M.: Treatment of advanced mammary cancer with testosterone. J. Amer. med. Ass. 138, 187 (1948).
Cutler, S. J.: In: Clinical Evaluation in Breast Cancer. Eds.: J. L. Haywardand R. D. Bulbrook. London-New York: Academic Press 1966, p. 214.
DE Hertogh, R., Pearlman, W. H.: Metabolism and Localisation of Estrone-6,7-H3 in Breast Cancer. Fed. Proc. 23, 276 (1964).
Deshpande, N., Bulbrook, R. D., Belzer, F. O.: Comparison between uptake of radioactivity by normal and neoplastic human breast tissue after single injection and intravenous infusion of tritiated testosterone. J. Endocr. 34, 125 (1966 a).
Deshpande, N., Bulbrook, R. D., Belzer, F. O.: An apparent selective accumulation of progesterone by the human breast. Excerpta Medica Internat. Congress. Series No. 132, 750 (1966 b).
Jensen, V., Bulbrook, R. D.: Accumulation of triated oestradiol by human breast tissue. Steroids 10, 219 (1967).
Donovan, A. J., Bethune, J. E., Berne, T. V.: Hypercalcaemia in patients with advanced mammary cancer and osseous metastases. Effect of hormone therapy and schedule of treatment. Amer. Surg. 32, 673 (1966).
Douglas, M.: The treatment of advanced breast cancer by hormone therapy. Brit. J. Cancer 6, 32 (1952).
Ellis, F., Parker, J. R., Bulbrook, R. D., Deshpande, N.: The uptake of radioactivity by normal and neoplastic human breast tissues after administration of tritiated testosterone. Brit. J. Surg. 52, 54 (1965).
Emerson, W. J., Kennedy, B. J., Graham, J. N., Nathanson, I. T.: Pathology of primary and recurrent carcinoma of the human breast after administration of steroid hormones. Cancer 6, 641 (1953).
Farrow, J. H., Woodard, H. Q.: The influence of Androgenic and Estrogenic substances on serum calcium. J. Amer. med. Ass. 118, 339 (1942).
Folca, P. J., Glascock, R. F., Irvine, W. T.: Studies with tritium labelled hexoestrol in advanced breast cancer. Lancet 1961 II, 796.
Foss, G. L.: Palliative hormone therapy of advanced mammary cancer. Lancet 1956 I, 651. GALTON, D. A. G.: Androgen therapy in 70 cases of advanced mammary carcinoma. Brit. J. Cancer 4, 20 (1950).
Goldenberg, I. S.: Testosterone propionate therapy in breast cancer. J. Amer. med. Ass. 188, 1069 (1964).
Bailar, J. C., Lowry, R.: Survival of women with hormonally treated breast cancer. Surg. Gynec. Obstet. 119, 785 (1964).
Gordan, G. S.: Hormonal effects of nonendocrine tumors with special reference to the hypercalcemia of breast cancer. In: Current Concepts in Breast Cancer. Eds.: A. Segaloff, K. K. Meyers, and S. Debakey. Baltimore: Williams and Wilkins 1967, p. 132.
Cantino, R. J., Erhardt, L., Hansen, J., Lubich, W.: Osteolytic sterol in human breast cancer. Science 151, 1226 (1966).
Gowing, N. F. C.: Histological changes in response to therapy. In: Clinical Evaluation in Breast Cancer. Eds.: J. L. Haywardand R. D. Bulbrook. LONDON-NEW York: Academic Press 1966, p. 53.
Hayward, J. L.: An evaluation of some factors affecting oestrogen response in the treatment of advanced cancer of the breast. Guy’s Hosp. Rep. 106, 254 (1957).
Hayward, J. L.: Assessment of response to treatment at Guy’s Hospital Breast Clinic. The estimation of the Mean Clinical Value. In: Clinical Evaluation in Breast Cancer. Eds.: J. L. HAYWARD and R. D. BULBROOK. London-New York: Academic Press 1966, pp. 131, 285.
Bulbrook, R. D.: Urinary steroids and prognosis in breast cancer. In: Prognostic Factors in Breast Cancer. Eds.: A. P. M. Forrest and P. B. Kunkler. Edinburgh-London: Livingstone 1968, p. 383.
Jensen, E. V., Jacobson, H. I.: Basic guides to the mechanism of estrogen action. Recent Progr. Hormone Res. 18, 387 (1962).
Kennedy, B. J.: Diethylstilbestrol versus testosterone therapy in advanced breast cancer. Surg. Gynec. Obstet. 120, 1246 (1965).
Kennedy, B. J.: Hormone therapy for advanced breast cancer. Cancer 18, 1551 (1965).
Kennedy, B. J.: Brown, J. H.: Combined estrogenic and androgenic hormone therapy in advanced breast cancer. Cancer 18, 431 (1965).
King, R. J., Cowan, D. M., Inman, D. R.: The uptake of (6.7–3-H) oestradiol by dimethylbenzathracene-induced rat mammary tumours.
Koller, P. C.: Influences of synthetic oestrogens upon advanced malignant disease. Addendum to A. Haddow, J. M. Watkinson, and E. Paterson. Brit. med. J. 1944 II, 393. Lewison, E. L., TRIMBLE, F. H.: Advanced mammary carcinoma, treated with sex hormones.
J. Amer. med. Ass. 162, 1429 (1956).
Meakin, J. W.: Personal Communication (1967).
Allt, W. E. C., Beale, F. A., Brown, T. C., Bulbrook, R. D., Clark, R. M., Fitz-Patrick, P. J., HawkinsN. V., Hayward, J. L., Jenkins, R. D. T.: A preliminary report of two studies of adjuvant treatment of primary breast cancer. In: Prognostic Factors in Breast Cancer. Eds.: A. P. M. FORREST and P. B. KUNKLER. Edinburgh-London: Livingstone 1968, p. 157.
Munson, P. L., Tashjian, A. H., Levine, L.: Evidence for parathyroid hormone in non-parathyroid tumours associated with hypercalcemia. Cancer Res. 25, 1062 (1965).
Nathanson, I. T.: Hormones in relation to tumours of the female. Prog. Gynaecology 2, 218 (1950).
Prudente, A.: Postoperative prophyllaxis of recurrent mammary cancer with testosterone propionate. Surg. Gynec. Obstet. 80, 575 (1945).
Quincey, R. V., Gray, C. H.: Uptake of (1,2–3H) 17a Methyltestosterone by breast carcinoma and other tissues of human subjects. Brit. J. Cancer 20, 271 (1966).
Segaloff, A.: Assessment of response to treatment by the Co-operative Breast Cancer Group. In: Clinical Evaluation in Breast Cancer. Eds.: J. L. HAYWARD and R. D. BULBROOK. London-New York: Academic Press 1966, pp. 125, 275.
Segaloff, A.: Hormones and breast cancer. Recent Progr. Hormone Res. 22, 351 (1966).
Horwitt, B. N., Carabisi, R. A., Murison, P. J., Schlosser, J. V.: Hormonal therapy in cancer of the breast. V. The effect of methyltestosterone on clinical course and hormonal excretion. Cancer 6, 483 (1953).
Segaloff, A.: Weeth, J. B., Meyer, K. K., Rongone, E. L., Cunningham, M. E. G.: Hormonal therapy in cancer of the breast. XIX. Effect of oral administration of d1 testololactone on clinical course and hormone excretion. Cancer 15, 633 (1962).
Segaloff, A.: Rongone, E. L., Murison, P. J., Bowers, C. Y.: Hormonal therapy in cancer of the breast. XVI. The effect of dl testololactone on clinical course and hormonal excretion. Cancer 13, 10–17 (1960).
Sherwood, L. M., O’riordan, J. L., Aurbach, G. D.: Production of parathyroid hormone by nonparathyroid tumors. J. clin. Endocr. 27, 140 (1967).
Thalassinos, N., Joflin, G. F.: Phosphate treatment of hypercalcaemia due to carcinoma. Brit. med. J. 1968 II, 14.
Virchow, R.: Virchows Arch. path. Anat. 8, 103 (1855).
Wali’ole, A. L., Paterson, E.: Synthetic oestrogens in mammary cancer. Lancet 1949 II, 783.
Walser, M., browder, A. A.: Ion association III: The Effect of sulfate infusion on calcium excretion. J. clin. Invest. 38, 1404 (1959).
Wolff, B.: The differential cell count in cancer of the breast and response to hormone therapy. Guy’s Hosp. Rep. 106, 53 (1957).
Author information
Authors and Affiliations
Rights and permissions
Copyright information
© 1970 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Hayward, J. (1970). Androgens and Oestrogens. In: Hormones and Human Breast Cancer. Recent Results in Cancer Research, vol 24. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-87015-6_5
Download citation
DOI: https://doi.org/10.1007/978-3-642-87015-6_5
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-87017-0
Online ISBN: 978-3-642-87015-6
eBook Packages: Springer Book Archive